<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004408</url>
  </required_header>
  <id_info>
    <org_study_id>199/13296</org_study_id>
    <secondary_id>CYTRX-C97-1248</secondary_id>
    <secondary_id>CYTRX-FDR001433</secondary_id>
    <nct_id>NCT00004408</nct_id>
  </id_info>
  <brief_title>Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mast Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CytRx</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mast Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Assess the efficacy of poloxamer 188 in reducing the duration of painful&#xD;
      vaso-occlusive crisis in patients with sickle cell disease.&#xD;
&#xD;
      II. Assess the effect of poloxamer 188 on duration and intensity of pain, total analgesic&#xD;
      use, and length of hospitalization of these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study.&#xD;
      Patients are stratified according to hydroxyurea use.&#xD;
&#xD;
      Patients are randomized to treatment poloxamer 188 or placebo. Treatment begins within 12&#xD;
      hours of presentation with crisis. Patients receive poloxamer 188 or placebo by continuous&#xD;
      infusion for 48 hours. Pain is assessed before, during, and after treatment.&#xD;
&#xD;
      Patients are followed on days 7-14 and 28-35.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1997</start_date>
  <completion_date type="Actual">November 1999</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>300</enrollment>
  <condition>Sickle Cell Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>poloxamer 188</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Sickle cell disease confirmed by electrophoresis or high pressure liquid&#xD;
             chromatography&#xD;
&#xD;
          -  At least one prior documented painful crisis episode but no greater than 10 crises per&#xD;
             year for the last two years&#xD;
&#xD;
          -  Sudden onset of acute pain lasting 4-12 hours and involving at least one site&#xD;
&#xD;
          -  Severe crisis pain that requires parenteral analgesics and hospitalization, but not&#xD;
             within the preceding 2 weeks&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  Surgery: At least 2 weeks since prior major surgery No concurrent surgery&#xD;
&#xD;
          -  Other: At least 2 weeks since prior puncture of noncompressible vessels No prior&#xD;
             therapy using poloxamer 188 No concurrent investigational drug No concurrent use of&#xD;
             nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Hematopoietic: No significant bleeding or bleeding disorder&#xD;
&#xD;
          -  Hepatic: ALT no greater than 2 times normal&#xD;
&#xD;
          -  Renal: No active renal disease Creatinine no greater than 1.0 mg/dL OR Creatinine&#xD;
             clearance greater than 50 mL/min Protein less than 300 mg/dL&#xD;
&#xD;
          -  Cardiovascular: No evidence of acute myocardial ischemia or infarction&#xD;
&#xD;
          -  Neurologic: At least 6 months since prior cerebrovascular accident or seizure&#xD;
&#xD;
          -  Other: Not pregnant Fertile patients must use effective contraception during and for&#xD;
             at least 30 days after treatment No history of chronic bacterial osteomyelitis No&#xD;
             history of drug or alcohol abuse At least 6 months since prior use of illicit drug&#xD;
             Have adequate IV access No crisis with life-threatening complications such as: Hepatic&#xD;
             or splenic sequestration Acute chest syndrome Aplastic crisis No known infection or&#xD;
             infection with encapsulated organism No evidence of septic shock Not concurrently&#xD;
             hospitalized for other conditions Not concurrently on hypertransfusion program&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Martin Emanuele</last_name>
    <role>Study Chair</role>
    <affiliation>CytRx</affiliation>
  </overall_official>
  <reference>
    <citation>Adams-Graves P, Kedar A, Koshy M, Steinberg M, Veith R, Ward D, Crawford R, Edwards S, Bustrack J, Emanuele M. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood. 1997 Sep 1;90(5):2041-6.</citation>
    <PMID>9292541</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 5, 2012</last_update_submitted>
  <last_update_submitted_qc>March 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>disease-related problem/condition</keyword>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>hematologic disorders</keyword>
  <keyword>pain</keyword>
  <keyword>rare disease</keyword>
  <keyword>sickle cell anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

